Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 4;12:879–890. doi: 10.2147/JPR.S185873

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Li et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Protein levels of t-Akt and p-Akt in corpus striatum (A-a). Three rats in each group. *P<0.05 compared to control animals, ^#P<0.05 compared to paclitaxel-treated rats. Protein levels of SIRT1 and PGC1α in corpus striatum (A, B). Protein levels of SIRT1and PGC1α in spinal dorsal horn (B). Protein levels of SIRT1and PGC1α in spinal dorsal horns (C). Protein levels of SIRT1and PGC1α in dorsal root ganglions (D). Paclitaxel reduced the expression levels of SIRT1 and PGC1α (*P<0.05), while resveratrol increased the expression of SIRT1 and PGC1α (*P<0.05); the protein levels of SIRT1 and PGC1α were suppressed by EX527 (*P<0.05).

Abbreviations: C, control group; R, resveratrol group; P, paclitaxel-treated group; R+P, resveratrol + paclitaxel-treated group; R+P+LY, pretreated-resveratrol + pretreated-paclitaxel + LY294002; E, pretreated-resveratrol + pretreated-paclitaxel + EX-527 group SIRT1, sirtuin 1.